Why Genmab Stock Was Marching Higher Today

Key Points

• Two prognosticators published updates on the biotech after it announced a major acquisition.

• It should soon be the owner of fellow European biotech Merus.

• 10 stocks we like better than Genmab A/s ›

One day after announcing a sizable acquisition, Denmark-based biotech Genmab (NASDAQ: GMAB) was doing well on the stock exchange Tuesday. A pair of analysts weighed in with bullish new takes on the company, helping push it to a nearly 5% price gain in late-session trading. That figure was many times higher than the marginal (0.1%) rise of the S&P 500 (SNPINDEX: ^GSPC) at that point.

An advantageous deal

Genmab has been in the spotlight following its announcement Monday that it agreed to acquire Netherlands-headquartered peer Merus. The price is $97 per share, which is to be paid in cash. All told, the deal is valued at $8 billion, and it has been approved by the boards of directors of both companies. It is expected to close in the first calendar quarter of 2026.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Image source: Getty Images.

Genmab wrote in its press release on the acquisition that it should "meaningfully accelerate Genmab's shift to a wholly owned model, expanding and diversifying the company's revenue, driving sustained growth into the next decade and contributing to Genmab's evolution into a biotechnology leader."

The two analysts publishing updates on Genmab Tuesday waxed bullish on the deal. Truist Securities analyst Asthika Goonewardene reiterated his buy recommendation on the stock, with a $46 per-share price target. According to reports, he wrote that Genmab is effectively acquiring Merus's late-stage developmental cancer drug petosemtamab for a very attractive price.

A 33% price target hike

Echoing similar sentiments, TD Cowen's Yaron Werber significantly raised his price target on Genmab; it now stands at $32 per share, well up from the preceding $24. Werber is more cautious about the stock, as he maintained his hold recommendation.

Should you invest $1,000 in Genmab A/s right now?

Before you buy stock in Genmab A/s, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Genmab A/s wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $650,607!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,114,716!*

Now, it’s worth noting Stock Advisor’s total average return is 1,068% — a market-crushing outperformance compared to 190% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of September 29, 2025

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Genmab A/s and Truist Financial. The Motley Fool has a disclosure policy.